Completion of the Third Clinical Trial - an Important Achievement for Medicortex Finland
Medicortex Finland Oy, a biotechnology company developing a breakthrough biomarker-based diagnostic kit for brain injury detection, completed collection of body fluid samples in its third large clinical study. Children and adolescents were recruited who visited the hospital with a suspected mild traumatic brain injury or concussion.
"Collecting the samples in this large clinical trial is a significant achievement for Medicortex, and represents an important step forward in the development of the ProbTBITM , a diagnostic kit for early detection of head injury" said Dr. Adrian Harel, Chief Executive Officer of Medicortex Finland. "Brain injury is a devastating condition leading to medical complications if not diagnosed. We have the opportunity to develop a portable non-invasive test for quick detection of mild traumatic brain injury (TBI) and concussion, and thereby help young patients and families who so desperately need it.” Dr. Harel added.
In the current clinical study Medicortex collected body fluid samples from total of 58 subjects, consisting of patients with head injury and uninjured healthy volunteers of matching age. A Finnish central hospital Satasairaala in Pori served as the study site recruiting the study subjects and collecting the body fluid samples. The next step is to analyze the samples for the presence and level of the unique biomarker and to demonstrate statistical difference between the patients with TBI and healthy control subjects. “The biomarker we are targeting has never before been used for mild brain injury detection. The fact that we can readily find it in easily accessible body fluids such as urine and saliva enable us to develop a user-friendly diagnostic kit for concussion and mild TBI detection”, says Dr. Harel.
Medicortex is working towards the validation of a traumatic brain injury (TBI) biomarker and incorporating it into a quick and reliable diagnostic kit that can be easily used by the first responders and healthcare professionals.
As Mediortex reaches this important milestone, preparations are underway for an Initial Public Offering and a listing of the company’s shares on a stock exchange. Medicortex is currently accepting subscription commitments in an ongoing Private Placement (pre-IPO) which will equip Medicortex with the necessary resources to ambitiously further developments and strengthen the company for its planned IPO. To read more about the investment case, please visit the Medicortex website (www.medicortex.fi/investors ).
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect head injuries in an easy way. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Once the company completes the biomarker development its next goal will be to develop an innovative drug to halt the progression of brain injury. Medicortex was founded by an Israeli neurobiologist Adrian Harel (Ph.D., MBA) and the company is based in Turku, Finland.
Key words: NFL, ice-hockey, rugby, brain injury, head injury, concussion, diagnostics, TBI, sport, professional athletes, boxing, early detection, trauma, clinical trial
This press release contains statements that are “forward-looking statements” that are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SD-RAVEN-INDUSTRIES,-INC12.5.2021 15:17:07 CEST | Press release
Raven Industries Launches the OMNi Brand
CA-SENTINELONE12.5.2021 15:02:07 CEST | Press release
SentinelOne Receives Highest Score for the Type A Use Case (“Lean Forward” Organizations) in the Gartner 2021 Critical Capabilities for Endpoint Protection Platforms
HIRO-CAPITAL12.5.2021 15:02:06 CEST | Press release
Hiro Capital Leads $6.4m Investment in Game Innovators Twin Suns Corp and FRVR
CA-CLOUDBLUE12.5.2021 15:02:06 CEST | Press release
New CloudBlue Revenue Management Solution Solves for Recurring Billing Reconciliation
MA-E-INK-HOLDINGS/NUCLER12.5.2021 14:55:05 CEST | Press release
Nuclera Acquires E Ink Digital Microfluidics Unit
CA-ESRI12.5.2021 14:02:11 CEST | Press release
Esri Partners with International Community to Scale GIS Technology for Sustainable Development
THALES12.5.2021 14:02:11 CEST | Press release
Thales Expands Its Access Management Capabilities to Offer a Unified Authentication Platform
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom